Strategic partnerships Creso Pharma has a track record of forming strategic partnerships across distribution and research, including recent collaborations for MDMA and psilocybin product import into Australia and agreements with distribution and pharmacy networks. Sales opportunities exist in expanding licensed product access and cross-border distribution.

International expansion Recent activity shows activity in Canada and Australia with plans to commercialise cannabis, hemp, and psychedelic-derived products. Target markets include licensed therapeutics and animal health segments, presenting cross-border revenue potential and regulatory navigation services as a sales angle.

Diverse product lines Portfolio includes pharmaceutical-grade cannabis and hemp products, Green Goo consumer line, pet care distribution via Gotro Global, and Halucenex Life Sciences assets. This breadth enables upsell across healthcare, animal health, and consumer wellness channels.

Funding signals Financing activity, including secured convertible notes, indicates ongoing growth and expansion plans. This may correlate with accelerated commercial initiatives, channel development, and larger purchase commitments from strategic customers.

Revenue potential Reported revenue range suggests a scalable business with opportunities to increase top-line through expanded product uptake, channel partnerships, and targeted B2B deals with distributors, clinics, and specialty retailers in regulated markets.